(Q34032505)

30 July 2017

1 reference

title

Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data (English)

1 reference

Parkinson's disease dementia

30 July 2017

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

Dag Aarsland

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

author name string

Peter Paul De Deyn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

James E Galvin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

Paolo Barone

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

publication date

7 July 2010

1 reference

CNS Neuroscience & Therapeutics

30 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

page(s)

428-441

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

Parkinson's disease: clinical features and diagnosis

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

How common are the "common" neurologic disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Clinical phenotype of Parkinson disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

A systematic review of prevalence studies of dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Dementia and survival in Parkinson disease: a 12-year population study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

The epidemiology of dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Cognitive deficits in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

The neuropsychiatry of Parkinson's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Cognitive change in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Cholinesterase inhibitors for Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Rivastigmine (Exelon) for dementia in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Evaluation of dementia rating scales in Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Evidence of a Monoaminergic-Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

The cognitive drug research computerized assessment system for demented patients: A validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00166.X

Mental symptoms in Parkinson's disease are important contributors to caregiver distress.

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Combined effect of age and severity on the risk of dementia in Parkinson's disease

1 reference

12 December 2020

The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil.

1 reference

12 December 2020

Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences

1 reference

12 December 2020

Clinical evaluation of Parkinson's disease dementia: association with aging and visual hallucination

1 reference

12 December 2020

A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease.

1 reference

12 December 2020

Parkinson's Disease Society Brain Bank, London: overview and research

1 reference

12 December 2020

Neuropathology of Parkinson's disease

1 reference

12 December 2020

Cholinesterase inhibition in Parkinson's disease

1 reference

12 December 2020

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

12 December 2020

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

10.1111/J.1755-5949.2010.00166.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6493905&resulttype=core&format=json

14 May 2020

1 reference